<DOC>
	<DOCNO>NCT01454739</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety recombinant human Factor VIII Fc fusion protein ( rFVIIIFc ) participant hemophilia A . The secondary objective study evaluate efficacy rFVIIIFc prevention treatment bleed episode participant hemophilia A .</brief_summary>
	<brief_title>Long-Term Safety Efficacy rFVIIIFc Prevention Treatment Bleeding Episodes Previously Treated Participants With Hemophilia A</brief_title>
	<detailed_description>Participant follow either prophylaxis on-demand regimen . The start dose study determine clinical profile participant precede study A-LONG - 997HA301 ( NCT01181128 ) , pediatric study 8HA02PED ( NCT01458106 ) 997HA307 ( NCT02083965 ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Key Subjects complete previous rFVIIIFc study ( NCT01181128 , NCT02083965 NCT01458106 ) Ability understand purpose risk study provide sign date informed consent ( assent , applicable ) . Key Confirmed positive hightiter inhibitor ( â‰¥5.00 BU/mL ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rFVIIIFc</keyword>
	<keyword>A-LONG Extension</keyword>
</DOC>